88 results
Page 3 of 5
424B5
n78e1mg1inu5ejc8l j0
21 Sep 20
Prospectus supplement for primary offering
5:02pm
424B5
k2val
17 Sep 20
Prospectus supplement for primary offering
5:25pm
8-K
EX-99.1
frej1
17 Sep 20
Other Events
6:39am
424B5
7y8zhgrh
21 Nov 19
Prospectus supplement for primary offering
8:31am
8-K
EX-1.1
1ih19i xdfw
20 Nov 19
Entry into a Material Definitive Agreement
4:50pm
424B5
oxfnorvctu 08
19 Nov 19
Prospectus supplement for primary offering
5:26pm
8-K
EX-99.1
317nsjdbg0dfp10y8x
8 Aug 19
Checkpoint Therapeutics Reports Second Quarter 2019 Financial Results and Recent Corporate Highlights
4:35pm
8-K
EX-99.1
guinl1rcb yy
9 May 19
Checkpoint Therapeutics Reports First Quarter 2019 Financial Results and Recent Corporate Highlights
5:13pm
8-K
EX-99.1
089ris
1 May 19
Checkpoint Therapeutics Announces Positive Interim Clinical Results of Anti-PD-L1 Antibody Cosibelimab
7:45am